GLP-1 Medications and Sleep Apnoea: Helpful Tool or Overhyped Cure? Contributed by CPAP Direct

GLP-1 peptide medications have quickly become one of the biggest talking points in health and weight loss, with many people now wondering whether they could also be the answer to obstructive sleep apnoea (OSA). While the research is promising, it’s important to separate the hype from the reality.

‍

Recent clinical studies have shown that GLP-1 medications can help reduce the severity of sleep apnoea in some patients, particularly those with a BMI of 30 or greater. The reason is simple: weight loss can reduce pressure around the airway, which may lower the number of breathing interruptions experienced during sleep.

But here’s the key point many people are missing: GLP-1 medications are not a cure for sleep apnoea.

‍

One year-long clinical trial found that the first 10% of body weight lost resulted in roughly a 20% reduction in sleep apnoea severity. While that sounds significant, the improvement often plateaued beyond that point. For example, someone with an AHI (Apnoea-Hypopnoea Index) of 25, classified as moderate OSA, may see that number reduce to just under 20 after losing 10% of their body weight. While improved, that person would still clinically have moderate sleep apnoea.

This highlights an important truth about OSA: sleep apnoea is not caused by weight alone. Airway anatomy, genetics, muscle tone, age, sleeping position, and other health factors all play a role. In fact, many people with sleep apnoea are not overweight at all.

‍

At CPAP Direct, we see daily how effective ongoing therapy and proper diagnosis are in improving sleep and overall health outcomes. GLP-1 medications may play a supporting role for some patients, but they should be viewed as part of a broader management strategy, not a silver bullet.

‍

For support on your journey toward healthier sleep, visit us in-store or at cpap.com.au.

‍